Best Creatine for Menopause: Evidence-Based Picks for Women 40+

Creatine spent two decades reputed as a supplement for male bodybuilders and college-age athletes. That framing was always too narrow, and the last five years of clinical research has made it indefensible. The most directly relevant body of work for this page — Smith-Ryan et al.'s 2021 women's lifespan review in Nutrients (PMID 33800439) and the 2025 menstruation-to-menopause review in the Journal of the International Society of Sports Nutrition (PMID 40371844) — has reframed creatine as one of the few non-hormonal supplements with credible evidence for the lean-mass, strength, and bone changes that define the perimenopause and post-menopause window. The biological case is clean. Estrogen decline in the menopause transition accelerates sarcopenia — the age-related loss of skeletal muscle — and reduces resistance-training adaptive response. Creatine works through a mechanism that is partly independent of the estrogen pathway: it expands muscle phosphocreatine stores, increasing the rate at which ATP is regenerated during high-effort contractions. In the context of resistance training, this allows for slightly higher training volume per session, which over months translates into measurably more lean mass and strength than training alone. Candow et al. (2021, PMID 34107512) tested 5 g/day creatine plus resistance training in older adults over 12 months and reported significant increases in lean mass and bone variables versus placebo plus resistance training. The Lanhers 2015 meta-analysis (PMID 25946994) of creatine and lower-limb strength found a consistent positive pooled effect across 24 RCTs. This page ranks three creatine monohydrate products — Thorne, Optimum Nutrition, and Nutricost — for women 40+ in the menopause transition. All three deliver a full 5 g serving of creatine monohydrate, the form with the entire relevant RCT evidence base; Thorne carries NSF Certified for Sport (independent SKU-level verification of label accuracy and banned-substance absence), and Optimum Nutrition's listing states Banned Substance Tested. Research suggests creatine may support lean mass, strength, and exercise performance in women across the menopause transition when paired with consistent resistance training, but no product on this page is a treatment for sarcopenia, osteoporosis, menopausal mood symptoms, or any medical condition. The distinction matters, and we'll be precise about it throughout. If you have severe bone-density loss, a diagnosed cardiovascular condition, kidney disease, or are managing a serious perimenopause symptom cluster, this page is a starting point for an informed clinician conversation, not a substitute for one.

Creatine is a naturally occurring nitrogenous compound that your body synthesizes from amino acids (arginine, glycine, methionine) at roughly 1 g/day, with additional intake from red meat and fish. Inside muscle cells, creatine is phosphorylated to phosphocreatine, which serves as the primary high-speed energy buffer for ATP regeneration during high-effort contractions. Resistance training — the activity most directly tied to lean-mass and strength outcomes in the menopause window — relies heavily on this phosphocreatine system. Supplemental creatine monohydrate at 3–5 g/day saturates muscle phosphocreatine stores over about 28 days (faster with a loading phase, slower without). At saturation, you can perform slightly more high-effort training volume per session — one or two more repetitions per set at near-maximal load, or a small increase in load at the same rep range. Over weeks and months, this small training-volume increase compounds into measurably greater lean mass and strength gains compared to training without creatine. This is the core mechanism behind the menopause-specific benefit documented in the Smith-Ryan reviews and the Candow 2021 RCT. A critical practical point: creatine's benefit is meaningfully tied to resistance training. Creatine without training delivers minimal lean-mass or strength benefit in the menopause window. The Smith-Ryan and Candow research consistently pairs the two interventions. If you're not currently doing resistance training, the highest-leverage step is starting a program — creatine is the adjunct, not the foundation. For cognitive and mood endpoints, the proposed mechanism is similar but acts in brain tissue rather than skeletal muscle: creatine supports ATP regeneration in neurons during high cognitive demand. Some research has explored whether this brain-energy buffering matters more during periods of cognitive stress or sleep deprivation. We are explicit that this mechanistic pathway has not yet been confirmed for menopause-specific cognitive endpoints in RCTs.

The single most important decision in creatine-for-menopause shopping is not the brand — it's the form. Creatine monohydrate has the entire menopause-relevant RCT evidence base behind it. Newer forms (creatine HCl, buffered creatine, creatine ethyl ester) have repeatedly failed to outperform monohydrate in head-to-head trials despite glossier marketing. Pay no premium for non-monohydrate forms — the evidence does not support it. Independent verification matters next. We only credit a testing or certification claim we can confirm directly on the product's Amazon listing. Thorne states NSF Certified for Sport — SKU-level independent testing for label accuracy and banned-substance absence. Optimum Nutrition's listing states Banned Substance Tested. Nutricost's listing does not carry a named sport-certification claim; it is GMP-certified and Non-GMO verified. All three are creatine monohydrate, the chemically identical active compound used in the cited clinical research — we do not assert a specific manufacturing source (such as Creapure) for any product here, because we could not verify that claim on any of the three listings. Dose translation is simple: 3–5 g/day, taken consistently. Loading phases (20 g/day for 5–7 days) saturate muscle phosphocreatine stores faster, but 5 g/day reaches the same saturation level in about 28 days. For a long-term menopause-window habit, skipping the loading phase is reasonable. Timing of dose (pre-workout, post-workout, morning) does not appear to matter meaningfully — consistency does. Certification is worth thinking through honestly. NSF Certified for Sport (Thorne) involves independent SKU-level testing for label accuracy, banned substance absence, and manufacturing compliance — meaningful if you compete in a sport with WADA, USADA, NCAA, or other governing-body testing. For a 52-year-old who wants to maintain strength and lean mass through perimenopause without testing concerns, Optimum Nutrition's Banned Substance Tested listing or Nutricost's GMP-certified, Non-GMO facility both cover the practical assurance most users need, at a fraction of Thorne's cost. Resistance training is the partner intervention. Creatine without training delivers minimal benefit in the menopause window. The Smith-Ryan and Candow research consistently pairs the two. If you're not currently lifting, starting a 2–3x/week resistance program (or working with a trainer to do so safely) is the highest-leverage step — creatine is the adjunct, not the foundation. Protein matters too: 1.2–1.6 g/kg/day is the range that supports both lean mass maintenance and the creatine response. Food-first note: creatine supplementation does not replace the menopause-window basics — protein-forward eating, resistance training 2–3x/week, adequate sleep, calcium and vitamin D adequacy for bone, and an informed conversation with a menopause-literate clinician about whether hormone therapy is right for you. Creatine layers on top of those, not instead of them.